Elelyso®

Understanding Elelyso® 

Elelyso® (taliglucerase alfa) is an enzyme replacement therapy (ERT) used to treat Type 1 Gaucher disease, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. This enzyme is responsible for breaking down glucocerebroside, a fatty substance that, when accumulated, leads to enlarged organs, anemia, low platelet counts, and bone complications.

How Elelyso® Works:

• Replaces the missing glucocerebrosidase enzyme
• Helps break down glucocerebroside, reducing its buildup in the liver, spleen, and bone marrow
• Improves symptoms such as organ enlargement, anemia, and bone pain

FDA Approval:

• Elelyso®: Approved in 2012 for adults, with subsequent expansion to include pediatric patients

For more information, please visit the Elelyso® patient website and speak with your healthcare provider to determine if Elelyso® is the right treatment option for you.